Postpartum anti-D: can we safely reduce the dose?

被引:12
|
作者
Augustson, Bradley M. [1 ]
Fong, Elizabeth A.
Grey, Dianne E.
Davies, Janine I.
Erber, Wendy N.
机构
[1] PathW Lab Med WA, Transfus Unit, Perth, WA, Australia
[2] PathW Lab Med WA, Flow Cytometry Unit, Perth, WA, Australia
[3] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Clin Haematol & Blood Transfus, Cambridge, England
关键词
D O I
10.5694/j.1326-5377.2006.tb00414.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: postpartum. Design: flow cytometry. Participants and setting: 5148 consecutive Rhesus D-negative women aged 15-45 years who had FMH estimation by flow cytometry at a central laboratory in Western Australia in the 65 months between 1 August 1999 and 31 January 2005. Main outcome measures: Quantitation of FMH volume for adequate prophylactic anti-D administration in a timely fashion. Results: 90.4% (4651/5148) of the women had an FMH volume of 1.0 mL or less of Rh D-positive red cells, and 98.5% (5072/5148) had a volume of less than 2.5 mL. Only 0.4% of cases had an FMH volume of 6.0 mL or greater (range, 6.0-92.4 mL). Conclusions: This large retrospective audit shows that a currently available dose of 250 IU (50 mg) of anti-D would have been sufficient for 98.5% of the 5148 Rh D-negative women. On the basis of this evidence, a reduction in the recommended routine postpartum dose of anti-D from 625 IU to 250 IU when flow cytometric quantitation for FMH is available should be considered. Adopting such a strategy would ensure the ongoing provision of a valuable human blood product currently in limited supply.
引用
收藏
页码:611 / 613
页数:3
相关论文
共 50 条
  • [31] Is the recommended minimum dose of anti-D adequate considering the rise in obesity?
    Regan, F. A. M.
    Naftalin, J.
    Springer, V.
    Paterson-Brown, S.
    TRANSFUSION MEDICINE, 2008, 18 (04) : 266 - 268
  • [32] COMPARATIVE STUDY OF ANTIGLOBULIN ANTIBODIES AND RESIDUAL ANTI-D BETWEEN RECIPIENTS OF INTRAMUSCULAR ANTI-D IMMUNOGLOBULIN AND INTRAVENOUS PLASMA ANTI-D
    VOS, GH
    SHAPIRO, M
    BURGESS, BJ
    VOS, D
    VOX SANGUINIS, 1973, 24 (01) : 33 - 41
  • [33] RH TYPING WITH ALBUMIN-SERUM/ANTI-D AND DEXTRAN/ANTI-D
    DRACHMAN.O
    DANISH MEDICAL BULLETIN, 1967, 14 (03): : 55 - &
  • [34] Can we safely lower the RT dose with the use of high dose PF for advanced cervical cancer?
    Kawamura, M.
    Nakahara, R.
    Ishihara, S.
    Oie, Y.
    Takase, Y.
    Okumura, M.
    Ito, J.
    Ono, T.
    Itoh, Y.
    Naganawa, S.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1064 - S1065
  • [35] Can we safely compress time?
    1600, Mattingley Publ Co, Oakland, CA, USA (57):
  • [36] Why should intramuscular anti-D be different from intravenous anti-D? COMMENT
    Bussel, James B. B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (03) : 275 - 276
  • [37] Evidence-Based Labor and Delivery Management Can We Safely Reduce the Cesarean Rate?
    Caughey, Aaron B.
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2017, 44 (04) : 523 - +
  • [38] NHS Breast Screening Programme - Can we safely reduce our clinical recall rate?
    Birtchnell, Jennifer
    Hutchison, Gillian
    BREAST CANCER RESEARCH, 2019, 21
  • [39] Anti-TNF therapy - Can we reduce the cost?
    Abernethy, VE
    Novak, J
    Dawson, JK
    Lynch, MP
    RHEUMATOLOGY, 2005, 44 : I66 - I66
  • [40] Dwindling supplies of anti-D
    Nelson, M
    Popp, HJ
    Kronenberg, H
    MEDICAL JOURNAL OF AUSTRALIA, 1998, 168 (06) : 311 - 311